Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2013

01.04.2013 | Regional Cancer Therapies

Extrahepatic Disease Should Not Preclude Transarterial Chemoembolization for Metastatic Neuroendocrine Carcinoma

verfasst von: David Arrese, MD, Megan E. McNally, MD, Ravi Chokshi, MD, Enrique Feria-Arias, BS, Carl Schmidt, MD, MS, Dori Klemanski, DNP, CNP, Guy Gregory, MD, Hooman Khabiri, MD, Manisha Shah, MD, Mark Bloomston, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Transarterial chemoembolization (TACE) is often utilized for patients with inoperable neuroendocrine carcinoma liver metastases. Often, metastatic disease is not limited to the liver. The impact of extrahepatic disease (EHD) on outcomes and response after TACE has not been described.

Methods

We reviewed 192 patients who underwent TACE for large hepatic tumor burden, progression of liver metastases, or poorly controlled carcinoid syndrome due to neuroendocrine carcinoma. Demographics, clinicopathologic characteristics, response to TACE, complications, and survival were compared between patients with (n = 123) and without (n = 69) EHD.

Results

Demographics, histopathologic characteristics, and complications were similar between groups. As well, those with and without EHD had similar biochemical (85 vs. 88 %) and radiographic response (76 vs. 79 %) to TACE (all p = NS); however, symptomatic responses were improved in those with EHD (79 vs. 60 %, p = 0.01). The group without EHD had better overall survival compared to those with EHD disease at the time of TACE (median 62 vs. 28 months, p = 0.001).

Discussion

Although patients with EHD from neuroendocrine carcinoma experience shorter overall survival after TACE compared to those without EHD, they had similar symptomatic, biochemical, and radiographic response to TACE. Meaningful response to TACE is still possible in the presence of EHD and should be considered, particularly in those with carcinoid syndrome.
Literatur
1.
Zurück zum Zitat Berge T, Linell F. Carcinoid tumors. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand. 1976;84:322–30. Berge T, Linell F. Carcinoid tumors. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand. 1976;84:322–30.
2.
Zurück zum Zitat Pommier R. The role of surgery and chemoembolization in the management of carcinoid. Presented at California Carcinoid Fighters Conference, October 25, 2003. Pommier R. The role of surgery and chemoembolization in the management of carcinoid. Presented at California Carcinoid Fighters Conference, October 25, 2003.
3.
Zurück zum Zitat Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(Suppl 4): iv1–6. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(Suppl 4): iv1–6.
4.
Zurück zum Zitat Ruszniewsi P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion. 2000;62(Suppl 1):79–83.CrossRef Ruszniewsi P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion. 2000;62(Suppl 1):79–83.CrossRef
5.
Zurück zum Zitat Banzo J, Abos E, Prats P, et al. Carcinoid tumor and bone metastases: diagnosis by somatostatin receptor scintigraphy. Rev Esp Med Nucl. 2004;23:394–402.PubMedCrossRef Banzo J, Abos E, Prats P, et al. Carcinoid tumor and bone metastases: diagnosis by somatostatin receptor scintigraphy. Rev Esp Med Nucl. 2004;23:394–402.PubMedCrossRef
6.
Zurück zum Zitat Bloomston M, Shah M, Ellison EC, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11:264–71.PubMedCrossRef Bloomston M, Shah M, Ellison EC, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11:264–71.PubMedCrossRef
7.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhaeur EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef Therasse P, Arbuck SG, Eisenhaeur EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef
8.
Zurück zum Zitat Desai DC, O’Dorisio TM, Schirmer WJ, et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept. 2001;96:113–7.PubMedCrossRef Desai DC, O’Dorisio TM, Schirmer WJ, et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept. 2001;96:113–7.PubMedCrossRef
9.
Zurück zum Zitat Moertel CG. Karnofsky Memorial Lecture: an odyssey in the land of small tumors. J Clin Oncol. 1987;5:1503–22. Moertel CG. Karnofsky Memorial Lecture: an odyssey in the land of small tumors. J Clin Oncol. 1987;5:1503–22.
10.
Zurück zum Zitat Ramage JK, Davies AH. Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat Cancer. 2003;10:483–6.PubMedCrossRef Ramage JK, Davies AH. Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat Cancer. 2003;10:483–6.PubMedCrossRef
11.
Zurück zum Zitat Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006;13:72–8.PubMed Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006;13:72–8.PubMed
12.
Zurück zum Zitat Gupta S, Johnson MM, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variable affecting response rates and survival. Cancer. 2005;104:1590–602.PubMedCrossRef Gupta S, Johnson MM, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variable affecting response rates and survival. Cancer. 2005;104:1590–602.PubMedCrossRef
14.
Zurück zum Zitat Oberg K. The ultimate biochemical diagnosis of gastro-entero-pancreatic tumours. Digestion. 1996;57(Suppl 1):45–7.PubMed Oberg K. The ultimate biochemical diagnosis of gastro-entero-pancreatic tumours. Digestion. 1996;57(Suppl 1):45–7.PubMed
15.
Zurück zum Zitat Kimura N, Funakoshi A, Aunis D, Tateishi K, Miura, Nagura H. Immunohistochemical localization of chromostatin and pancreastatin, chromogranin A—derived bioactive peptides, in normal and neoplastic neuroendocrine tissues. Endocr Pathol. 1995;6:35–43.PubMedCrossRef Kimura N, Funakoshi A, Aunis D, Tateishi K, Miura, Nagura H. Immunohistochemical localization of chromostatin and pancreastatin, chromogranin A—derived bioactive peptides, in normal and neoplastic neuroendocrine tissues. Endocr Pathol. 1995;6:35–43.PubMedCrossRef
16.
Zurück zum Zitat van Persijn van Meerten EL, Gelderblum H, Bloem JL. RECIST revisited: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 2010;20:1456–67. van Persijn van Meerten EL, Gelderblum H, Bloem JL. RECIST revisited: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 2010;20:1456–67.
17.
Zurück zum Zitat Gupta S, Yao JC, Ajani JA, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience. Cancer J. 2003;9:261–7.PubMedCrossRef Gupta S, Yao JC, Ajani JA, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience. Cancer J. 2003;9:261–7.PubMedCrossRef
18.
Zurück zum Zitat Kress O, Wagner R, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization for advanced liver metastases of neuroendocrine tumors—a retrospective single-center analysis. Digestion. 2003;68:94–101.PubMedCrossRef Kress O, Wagner R, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization for advanced liver metastases of neuroendocrine tumors—a retrospective single-center analysis. Digestion. 2003;68:94–101.PubMedCrossRef
19.
Zurück zum Zitat Scherübl H. Tumor biology and prognosis of gastrointestinal carcinoids. J Clin Oncol. 2008;26:6012–3.PubMedCrossRef Scherübl H. Tumor biology and prognosis of gastrointestinal carcinoids. J Clin Oncol. 2008;26:6012–3.PubMedCrossRef
Metadaten
Titel
Extrahepatic Disease Should Not Preclude Transarterial Chemoembolization for Metastatic Neuroendocrine Carcinoma
verfasst von
David Arrese, MD
Megan E. McNally, MD
Ravi Chokshi, MD
Enrique Feria-Arias, BS
Carl Schmidt, MD, MS
Dori Klemanski, DNP, CNP
Guy Gregory, MD
Hooman Khabiri, MD
Manisha Shah, MD
Mark Bloomston, MD
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2786-4

Weitere Artikel der Ausgabe 4/2013

Annals of Surgical Oncology 4/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.